Krishnan Suma, President of R&D at Krystal Biotech (KRYS), has filed 73 Form 4 transactions, all in a single company and all on the sell side. The total value of those sales is $41.56 million. There are no open-market purchases, no option exercises, and no acquisitions of any kind in the record. The pattern is consistent: Suma sells KRYS stock, and she sells it in size.
The most recent cluster came on September 4, 2026, when she filed 13 separate sale transactions totaling roughly $8.1 million. Individual sales ranged from $146,255 to $1.42 million. That followed a June 4, 2026 batch of 11 sales worth about $7.9 million, with the largest single transaction at $3.92 million. The earliest trade in the recent window, dated March 4, 2026, was a $452,918 sale. Across the last three quarterly filing dates, she has sold on every single one.
The absence of any buy-side activity matters for context. Suma has not used a Form 4 to acquire shares, whether by purchase, grant, or exercise, at any point in this filing history. Her disclosed activity is entirely dispositive. The dollar figures are large relative to typical insider filings, and the concentration in one ticker means her selling is tied directly to Krystal Biotech's stock price. The data shows a sustained, one-directional pattern of reducing her position in KRYS.
AI-assisted summary